Australia markets close in 1 hour 21 minutes

    +76.40 (+1.13%)
  • ASX 200

    +76.60 (+1.17%)

    +0.0032 (+0.44%)
  • OIL

    +0.37 (+0.86%)
  • GOLD

    -13.90 (-0.76%)

    +66.54 (+0.27%)
  • CMC Crypto 200

    +6.86 (+1.90%)

    +0.0024 (+0.39%)

    -0.0050 (-0.47%)
  • NZX 50

    +60.80 (+0.49%)

    -0.50 (-0.00%)
  • FTSE

    -17.61 (-0.28%)
  • Dow Jones

    +327.79 (+1.12%)
  • DAX

    -10.28 (-0.08%)
  • Hang Seng

    +20.33 (+0.08%)
  • NIKKEI 225

    +669.27 (+2.62%)

Did Osmotica Pharmaceuticals' (NASDAQ:OSMT) Share Price Deserve to Gain 72%?

Simply Wall St
·3-min read

The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by picking above-average stocks. For example, the Osmotica Pharmaceuticals plc (NASDAQ:OSMT) share price is up 72% in the last year, clearly besting the market return of around 18% (not including dividends). If it can keep that out-performance up over the long term, investors will do very well! Note that businesses generally develop over the long term, so the returns over the last year might not reflect a long term trend.

See our latest analysis for Osmotica Pharmaceuticals

Because Osmotica Pharmaceuticals made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last year Osmotica Pharmaceuticals saw its revenue shrink by 14%. The stock is up 72% in that time, a fine performance given the revenue drop. To us that means that there isn't a lot of correlation between the past revenue performance and the share price, but a closer look at analyst forecasts and the bottom line may well explain a lot.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).


If you are thinking of buying or selling Osmotica Pharmaceuticals stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

Osmotica Pharmaceuticals boasts a total shareholder return of 72% for the last year. The more recent returns haven't been as impressive as the longer term returns, coming in at just 2.1%. It seems likely the market is waiting on fundamental developments with the business before pushing the share price higher (or lower). While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 2 warning signs we've spotted with Osmotica Pharmaceuticals .

But note: Osmotica Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email